These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 2645705)

  • 21. Living-Donor Kidney Transplant With Preformed Donor-Specific Antibodies.
    Itabashi Y; Aikawa A; Muramatsu M; Hyoudou Y; Shinoda K; Takahashi Y; Sakurabayashi K; Mizutani T; Oguchi H; Arai T; Kawamura T; Hamasaki Y; Sakai K; Shishido S
    Exp Clin Transplant; 2019 Jan; 17(Suppl 1):43-49. PubMed ID: 30777522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HLA-DR1 is a low responsiveness antigen in human kidney transplant recipients.
    Cicciarelli J
    Clin Transpl; 1987; ():381-91. PubMed ID: 3154437
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo heat inactivation of serum can distinguish false positive cross matches in renal transplants.
    Riley AA; Klingman L; Brier ME; Chand DH
    Int J Artif Organs; 2016 Feb; 39(2):63-7. PubMed ID: 26953900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients.
    Meng HL; Jin XB; Li XT; Wang HW; Lü JJ
    Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HLA-DR associated immune responsiveness.
    Cook DJ
    Clin Transpl; 1986; ():247-56. PubMed ID: 3154411
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The flow cytometric crossmatch and early renal transplant loss.
    Mahoney RJ; Ault KA; Given SR; Adams RJ; Breggia AC; Paris PA; Palomaki GE; Hitchcox SA; White BW; Himmelfarb J
    Transplantation; 1990 Mar; 49(3):527-35. PubMed ID: 2138366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HLA-DQ matching in cadaveric renal transplantation.
    Freedman BI; Thacker LR; Heise ER; Adams PL
    Clin Transplant; 1997 Oct; 11(5 Pt 2):480-4. PubMed ID: 9361945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful transplantation after conversion of a positive crossmatch to negative by dissociation of IgM antibody.
    Tellis VA; Matas AJ; Senitzer D; Louis P; Glicklich D; Soberman R; Veith FJ
    Transplantation; 1989 Jan; 47(1):127-9. PubMed ID: 2643222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The UNOS Scientific Renal Transplant Registry.
    Cecka JM
    Clin Transpl; 1996; ():1-14. PubMed ID: 9286555
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Flow cytometry-detected IgG is not a contraindication to renal transplantation: IgM may be beneficial to outcome.
    Kerman RH; Susskind B; Buyse I; Pryzbylowski P; Ruth J; Warnell S; Gruber SA; Katz S; Van Buren CT; Kahan BD
    Transplantation; 1999 Dec; 68(12):1855-8. PubMed ID: 10628764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Luminex Solid-Phase Crossmatch for De Novo Donor-Specific Antibodies in Living-Donor Related Transplants.
    Mehrotra S; Sharma RK; Mayya M; Gupta A; Prasad N; Kaul A; Bhadauria DS
    Exp Clin Transplant; 2017 Aug; 15(4):394-399. PubMed ID: 28447925
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HLA phenotypes of ESRD patients are risk factors in the panel-reactive antibody (PRA) response.
    Heise E; Manning C; Thacker L
    Clin Transplant; 2001; 15 Suppl 6():22-7. PubMed ID: 11903382
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence that matching for HLA antigens significantly increases transplant survival in 1001 renal transplants performed in the northwest region of England.
    Dyer PA; Johnson RW; Martin S; Bakran A; Gokal R; Harris R; Mallick NP; Manos J; Orr WM; Pearson RC
    Transplantation; 1989 Jul; 48(1):131-5. PubMed ID: 2665219
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The roles of sex, race, and ABO groups.
    Cecka JM
    Clin Transpl; 1986; ():199-221. PubMed ID: 3154403
    [TBL] [Abstract][Full Text] [Related]  

  • 35. B-Cell crossmatching and kidney allograft outcome in 9031 United States transplant recipients.
    Mahoney RJ; Taranto S; Edwards E
    Hum Immunol; 2002 Apr; 63(4):324-35. PubMed ID: 12039415
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful transplantation of cyclosporine-treated allograft recipients with serologically positive historical, but negative preoperative, donor crossmatches.
    Kerman RH; Flechner SM; Van Buren CT; Lorber MI; Kahan BD
    Transplantation; 1985 Dec; 40(6):615-9. PubMed ID: 3907031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of patients at risk for inferior renal allograft outcome by a strongly positive B cell flow cytometry crossmatch.
    Lazda VA
    Transplantation; 1994 Mar; 57(6):964-9. PubMed ID: 8154047
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiscreen serum analysis of highly sensitized renal dialysis patients for antibodies toward public and private class I HLA determinants. Implications for computer-predicted acceptable and unacceptable donor mismatches in kidney transplantation.
    Duquesnoy RJ; White LT; Fierst JW; Vanek M; Banner BF; Iwaki Y; Starzl TE
    Transplantation; 1990 Sep; 50(3):427-37. PubMed ID: 2402792
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hyperacute rejections of two consecutive renal allografts and early loss of the third transplant caused by non-HLA antibodies specific for endothelial cells.
    Sumitran-Karuppan S; Tyden G; Reinholt F; Berg U; Moller E
    Transpl Immunol; 1997 Dec; 5(4):321-7. PubMed ID: 9504155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Weak humoral posttransplant alloresponse after a well-HLA-matched cadaveric kidney transplantation.
    Matinlauri IH; Kyllönen LE; Eklund BH; Koskimies SA; Salmela KT
    Transplantation; 2004 Jul; 78(2):198-204. PubMed ID: 15280678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.